Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724556 | 1.00 | OGA (0.39) | OGAHRH3ABCB1ACACBHDAC3 | |
| SCHEMBL5724268 | 0.85 | OGA (0.36) | OGAHRH3ABCB1ACACBAR | |
| SCHEMBL5724265 | 0.85 | OGA (0.36) | OGAHRH3ABCB1ACACBAR | |
| SCHEMBL5723799 | 0.84 | OGA (0.37) | OGAHRH3ABCB1ACACBAR | |
| SCHEMBL5723794 | 0.84 | OGA (0.37) | OGAHRH3ABCB1ACACBAR | |
| SCHEMBL5724230 | 0.84 | OGA (0.46) | OGAHRH3ACACBL3MBTL1ACKR3 | |
| SCHEMBL5724225 | 0.83 | OGA (0.35) | OGAABCB1ACACBL3MBTL1ACKR3 | |
| SCHEMBL5724233 | 0.81 | OGA (0.35) | OGAABCB1ACACBACKR3KMT2A | |
| SCHEMBL5724234 | 0.81 | OGA (0.35) | OGAABCB1ACACBACKR3KMT2A | |
| SCHEMBL5724033 | 0.81 | OGA (0.34) | OGAABCB1ACACBL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | OGA 3469/4885HRH3 3678/4885ABCB1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.